25, November 2022, Precision diagnostics platform provider NGeneBio announced that it has inked a deal with NUPCO(National Unified Procurement Company) to supply its NGS panel for hematologic Malignancies, HEMEaccuTest™. According to the contract, NGeneBio will deliver kits based on a separate confirmed purchase order at the contract unit price for two years from the first quarter of 2023. 

NUPCO was established in 2009 by the government of Saudi Arabia. NUPCO has been centralizing procurement, warehousing, distribution, and re-exporting of pharmaceuticals, medical equipment and supplies for the benefit of all public hospitals and healthcare facilities.

NGeneBio participated in the tender for blood cancer precision diagnosis products ordered by the Saudi government through a local distributor and will deliver about 4,000 blood cancer NGS panel kits, HEMEaccuTest™ to NUPCO through a local distributor. The products are currently being evaluated at Saudi hospitals, and blood cancer precision diagnosis tests will be conducted at Saudi hospitals as early as next year with NGeneBio's products supplied through NUPCO.

NGeneBio's blood cancer precision diagnosis product, HEMEaccuTest™, is Asia's first CE-IVD certified blood cancer NGS panel in 2018. HEMEaccuTest™ was developed to detect blood cancer-related DNA and RNA, respectively. DNA test products can detect about 100 genes at once, and RNA test products can detect about 50 genes at once. In particular, It is an important determinant of the supply selection that NGeneBio’s panel is provided with analysis software NGeneAnySys, which can analyze major mutations that cause blood cancer and provides personalized prescriptions.